Viewing data from:

TESLASCAN

NDA

MANGAFODIPIR TRISODIUM | N020652 | IC TARGETS AS

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

1 trial from ClinicalTrials.gov — 1 recruiting

Trial	Phase	Status	Sponsor	Enrollment	Dates
Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy NCT02531880	Phase 1	Recruiting	National Institute of Neurological Disorders and Stroke (NINDS)	40	2024-11-19 → 2030-07-01

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jul 8, 2002	SUPPL -3	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 37.9MG/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Nov 26, 1997

No patent or exclusivity listings for this strength.